Conjunctivally Applied BDNF Protects Photoreceptors from Light-Induced Damage by Elisa Cerri, Nicola Origlia, Benedetto Falsini, Davide Barloscio, Carlotta Fabiani,Marco Sanso', Sara Ottino, Luca Giovannini, and Luciano Domenici.
DOI: 10.1167/tvst.4.6.1
Article
Conjunctivally Applied BDNF Protects Photoreceptors from
Light-Induced Damage
Elisa Cerri1, Nicola Origlia1, Benedetto Falsini2, Davide Barloscio1, Carlotta Fabiani1,
Marco Sanso`3, Sara Ottino3, Luca Giovannini4, and Luciano Domenici1,5
1 Neuroscience Institute of the National Council of Research (CNR), Pisa, Italy
2 Institute of Ophthalmology, Policlinico Gemelli, Catholic University, Rome, Italy
3 ITH S.r.l., Pisa, Italy
4 Department of Translational Research on New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy
5 Department of Biotechnological and Applied Clinical Sciences (DISCAB), University of L’Aquila, L’Aquila, Italy
Correspondence: Luciano Domenici,
CNR Neuroscience Institute, Via G.
Moruzzi 1, 56100 Pisa, Italy. e-mail:
domenici@in.cnr.it
Received: 11 June 2015
Accepted: 25 September 2015
Published: 2 November 2015
Keywords: neuroprotection; ERG;
photoreceptors degeneration;
topical eye treatment; retinopa-
thies
Citation: Cerri E, Origlia N, Falsini B,
Barloscio D, Fabiani C, Sanso` M,
Ottino S, Giovannini L, Domenici L.
Trans Vis Tech. 2015;4(6):1, doi:
10.1167/tvst.4.6.1.
Purpose: To test whether the topical eye treatment with BDNF prevents the effects of
continuous light exposure (LE) in the albino rat retina.
Methods: Two groups of albino rats were used. The first group of rats received an
intraocular injection of BDNF (2 lL, 1 lg/lL) before LE, while the second group was
treated with one single drop of BDNF (10 lL, 12 lg/lL) dissolved in different types of
solutions (physiological solution, the polysaccharide fraction of Tamarind gum, TSP,
and sodium carboxy methyl cellulose), at the level of conjunctival fornix before LE. The
level of BDNF in the retina and optic nerve was determined by enzyme-linked
immunosorbent assay. We recorded the flash electroretinogram (fERG) in dark
adapted rats 1 week after LE. At the end of the recording session, the retinas were
removed and labeled so that the number of photoreceptors nuclear rows and
thickness of the outer nuclear layer was analyzed.
Results: Intravitreal injection of BDNF before LE prevented fERG impairment. Different
ophthalmic preparations were used for topical eye application; the TSP resulted the
most suitable vehicle to increase BDNF level in the retina and optic nerve. Topical eye
application with BDNF/TSP before LE partially preserved both fERG response and
photoreceptors.
Conclusions: Topical eye treatment with BDNF represents a suitable, noninvasive tool
to increase the retinal content of BDNF up to a level capable of exerting
neuroprotection toward photoreceptors injured by prolonged LE.
Translational Relevance: A collyrium containing BDNF may serve as an effective,
clinically translational treatment against retinal degeneration.
Introduction
Neurodegeneration of photoreceptors represents a
group of inherited (Mendelian, most of the cases) or
induced retinal diseases for which no treatment is
available; the neurodegeneration process is similar to
the programmed cell death occurring in different
nuclei of the central nervous system with progressive
apoptosis of photoreceptors. Molecules with neuro-
trophic actions including neurotrophic factors of
NGF family (neurotrophins) were shown to be
effective in slowing down cell death in various models
of neurodegenerative diseases.1–4 The biological
action of neurotrophins is mediated by specific
receptors present on the cell membrane. Various
types of neurotrophin receptors have been character-
ized: a low-affinity receptor (p75) capable of binding
NGF as well as other neurotrophins and a group of
tyrosine kinase type receptors (Trks) specific for each
neurotrophin. Trk receptors increase their autophos-
phorylation activity and trigger a cascade of intracel-
lular events responsible for cell survival and
differentiation, phenotype maintenance, and plastic-
ity.5 In the mammalian retina, BDNF and its TrkB
receptor are highly expressed.6–9 Genetic targeting of
BDNF, or disruption of BDNF signaling, impairs
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transmission of electrical signals from photoreceptors
to second-order neurons10 and results in alterations of
the inner retina.11 Remarkably, intraocular injection
of BDNF was capable of preventing light induced
apoptosis of photoreceptors in albino rats.12,13
So far BDNF, as well as other growth factors, has
been typically administered to the internal ocular
tissues by intravitreous or retrobulbar injection; these
methods of treatment are associated with the risk of
various complications such as the ocular bulb perfo-
ration and infections.14 In the present work, we
searched for an alternative strategy permitting an easy,
safe, and repeatable treatment to increase the level of
neurotrophic factors in the retina. To this aim, we
exploited the possibility of administering BDNF using
the external ophthalmic route, that is, in the form of
collyrium; previous results by our group showed that
topical eye application of BDNF was able to increase
the BDNF retinal content in the mouse and rat
retina.15 We have selected one model of neurodegen-
eration to study retinal protection by topical eye
application of BDNF. This model is based on light-
induced damage (light-damage) to the albino rat retina
caused by exposure to continuous bright light; this is
an in vivo model to induce a fast and synchronized
program of photoreceptor apoptosis.2 Exposure to
bright continuous light was previously used as a model
system to assess quantitatively the photoreceptor
survival-promoting activity of various neurotrophic
agents, including BDNF.12,13 In the present paper,
human recombinant BDNF was intravitreally injected
and topically applied at the level of conjunctival fornix
in separate groups of albino rats. Different vehicles
were used for topical eye application of BDNF; the
retina and optic nerve levels of the BDNF protein were
measured in tissue extracts taken at different times
after treatment using high sensitive enzyme-linked
immunosorbent assay (ELISA). The flash electroreti-
nogram (fERG) and histology of outer retina were
investigated in treated and untreated eyes of light
exposed (LE) albino rats. Our results clearly indicated
that topical eye application of BDNF in the form of
collyrium was able to preserve the retinal response to
flash stimuli and to prevent alteration of photorecep-
tors in light-damage of albino rat retinas.
Material and Methods
Ethics Statement
All experiments were conducted according to
Ministry of Health (the regulatory authority for
controlling the use of laboratory animals and ethics
on animal experiments in Italy) guidelines (Legislative
Decree n. 116/92) and in accordance with the
European Community guidelines (European Directive
86/609/EEC). The experimental protocol (IACUC
document) was approved by the Ministry of Health
(n. 152/2013; IACUC is renewed every 3 years). The
authors confirm their adherence to the ARVO
Statement for the Use of Animals in Ophthalmic
and Vision Research.
BDNF Preparations
Thirty-four 16-week-old male Wistar albino rats
(Charles River Italia, Lecco, Italy) were used. Before
BDNF administration, rats were anesthetized with an
intraperitoneal injection of Avertin at 2 mL/100 g
body weight (1.25% [w/v] 2,2,2-tribromoethanol and
2.5% [w/v] 2-methyl-2-butanol; Aldrich, St. Louis,
MO). Human recombinant BDNF (QED Bioscience,
Inc., San Diego, CA) at concentrations comprised
between 1 and 12 lg/lL was dissolved in a
physiological solution (0.9% NaCl) and applied as a
drop (10 lL) at the level of conjunctival fornix under
dissecting microscope (Leica, Germany); the site of
application was gently compressed for a few minutes.
In a second group of rats, we used the polysaccharide
fraction of Tamarind gum (TSP; 0.25%, Farmigea
Holding Srl, Pisa, Italy) or sodium carboxy methyl
cellulose (CMC; 0.2%, Farmigea Holding Srl) as
vehicles, with the aim to produce thickened ophthal-
mic solutions facilitating prolonged BDNF delivery.
In a parallel group of albino rats, BDNF was also
supplied using single intravitreal injection (human
recombinant BDNF at the concentration of 1 lg/lL
in 2 lL of 0.9% NaCl). Topical eye treatment and
intravitreal injection were performed 3 hours before
prolonged exposure to light (light damage) with
animals left to recover from anesthesia.
Light-Induced Damage
The protocol for light damage (photolesion)
derives from that described by LaVail et al.12 with
minor modifications. Briefly, albino rats were reared
on a 12-hour light/dark cycle, with the illumination
level below 60 photopic lux, until the day of LE. At
that time, the rats were housed separately in
transparent Plexiglas cages and exposed to continu-
ous light produced by four 36-W white fluorescent
bulbs (Osram Sylvania, Munich, Germany). Light
sources were suspended 30 cm above (two bulbs) and
under (two bulbs) cages to produce a uniform
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illumination of 1000 lux. Animals had free access to
food and water. After continuous illumination for 48
hours (LE), animals were returned in a room with a
12-hour light/dark cycle for 5 days before recording
and subsequent retinal histological analysis.
Flash Electroretinogram
Flash electroretinogram was performed according
to previously published methods.16,17 Briefly, the
electrophysiological signals were recorded through
gold plate electrodes inserted under the lower eyelids
in contact with the cornea, previously anesthetized
with oxybuprocaine (Novesine, Novartis Pharma,
Switzerland). Corneal electrodes from each eye were
referred to a needle electrode inserted subcutaneously
at the level of the corresponding ear region. The
different electrodes were connected to a two-channel
amplifier (LACE, Pisa, Italy). Animals were dark
adapted (360 minutes), anesthetized using Avertin as
described and loosely mounted in a stereotaxic
apparatus under dim red light with the body
temperature maintained at 37.58C and the heart rate
monitored; recordings were preferably performed at
noon to avoid amplitude oscillations linked to
circadian rhythms. FERG was evoked by 10-ms
single flashes of different luminances generated
through a Ganzfeld stimulator (LACE) in scotopic
conditions. The amplitude of the a- and b-wave for
each eye was plotted as a function of increasing
luminance (transfer curve); for each animal group the
mean a- and b-wave amplitude 6 standard error of
the mean (SEM) was plotted.
Histological Analysis
After fERG recording, rats were sacrificed and
their eyecups were harvested and fixed by immersion
in a solution of 4% paraformaldehyde (PFA) in 0.01
phosphate buffer (PB, at pH 7.4) in the light phase
during the diurnal cycle; a cut was made in the top of
eye cup for successive orientation (the 12:00 merid-
ian of eye was marked). Then, eye cups were washed
in PB several times and cryoprotected in 30% sucrose
in PB at 48C overnight. Eye cups were then
embedded in cryomatrix (Tissue Tek, Reichert-Jung,
Nuloch, Germany) and frozen. Serial frozen sections
(10 lm) were cut on a cryostat (Reichert-Jung)
perpendicular to the 12:00 meridian, starting from
the superior border of the cornea. We used two
sampling methods. In a preliminary series of
experiments, sampling was performed along the
vertical meridian, at a distance of 750 lm, this
resulting in 15 retinal sites of sampling according to
Maccarone et al.18; we used a window covering an
area of 250 3 250 lm. Since LE for 48 hours
dramatically reduced the thickness of the outer
nuclear layer (ONL) homogenously along the
vertical meridian, we decided to use a second
sampling method. We performed sampling at two
sites along the vertical meridian taken at different
distances from the optic nerve head: one site in the
peripheral retina (3.5 mm from the optic nerve head)
and one site in the central retina (1 mm from the
optic nerve head). In this way, two peripheral and
two central retinal regions (two regions for superior
and two regions for inferior quadrants, this resulting
in eight retinal sites; we used a window covering an
area of 2503250 lm) were selected along the vertical
meridian for each retina, and sampled together with
other retinas within each experimental group,
holding separate peripheral and central retinal sites.
We decided to use this second method unless
otherwise stated. Sections were collected onto
gelatin-coated slides, air-dried, and stored at 208C
until further processing. Propidium Iodide (Molec-
ular Probes; 1:1000 in phosphate-buffered saline;
Thermo Fisher Scientific, Waltham, MA), a nuclear
stain fluorescent in the red spectra, was used to
compare the number of rows of photoreceptors or
thickness of ONL. Images were taken by confocal
microscope (Leica) and fluorescence microscope
(Nikon, Japan). To quantify photoreceptors, the
number of nuclei rows in the ONL and the ONL
thickness were separately assessed for each retina.
Enzyme-Linked Immunosorbent Assay
Retinas and optic nerves were extracted in
anesthetized rats and immediately homogenized in
five volumes of 100 mM Tris buffer (pH 7.4)
containing 500 mM NaCl, 2% TritonX-100, 1%
NP40, 10% glycerol, and protease and phosphatase
inhibitors: 1 mM PMSF, 10 g/mL aprotinin, 1 g/mL
leupeptin (Sigma Aldrich, Milano, Italy). This ho-
mogenate was centrifuged at 10,000 rpm for 30
minutes, and the supernatant fraction was used for
ELISA. We performed a sandwich ELISA using the
BDNF Emax immunoassay system from Promega
(Promega Corporation, Madison, WI) to measure
retinal and optic nerve levels of BDNF. Briefly, 96-
well plates were coated with anti-BDNF monoclonal
antibody and incubated at 48C for 18 hours. The
plates were incubated in a blocking solution for 1
hour at room temperature, then samples were added.
The samples and BDNF standards were incubated for
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2 hours, followed by washing with the appropriate
buffer. Successively, the plates were incubated with
anti-human BDNF polyclonal antibody at room
temperature for 2 hours, washed, and then incubated
with specific anti-IgG antibody conjugated to horse-
radish peroxidase for 1 hour at room temperature.
The plates were finally incubated with chromogen
substrate to produce color reaction. The reaction was
stopped with 1M HCl, and absorbance was measured
at 450 nm using a microplate reader (Model 550, Bio-
Rad Laboratories, Milano, Italy).
Statistics
The statistical significance of differences between
untreated, control vehicle treated, and BDNF-treated
eyes was achieved using individual Student’s t-test
and one-way analysis of variance (ANOVA) for
ELISA and histological analysis; for fERG analysis,
we used two-way ANOVA (Sigma Stat) followed by
Holm-Sidak all-pairwise multiple comparison proce-
dure; P , 0.05 was considered significant.
Results
Previous reports12,13 showed that single intraocu-
lar injection of BDNF at the concentration comprised
between 1 and 10 lg/lL was able to protect retinal
cells in different animal models of retinal degenera-
tion,2 including light-damage. We repeated these
experiments in our experimental context. We used
intravitreal injection of BDNF 3 hours before LE (1
lg/lL in NaCl; volume ¼ 2 lL). After 3 hours from
BDNF treatment, the albino rats were exposed to
constant light (1000 Lux; LE) for 48 hours and,
successively, left to recover in their cages; 7 days after
light-damage (calculated from the first day of LE) rats
were anesthetized and dark adapted for fERG
recordings. Retinal responses to flashes of different
intensities in normal untreated eyes are reported in
Figure 1 (A) as single traces and Figure 1 (B, C) as the
plot of a- and b-wave amplitudes at different light
intensities (cd s/m2). We found that a single intraoc-
Figure 1. Flash ERG (fERG) in control and light-damaged rats. (A) Representative traces of dark-adapted fERG evoked at five different
luminances (top-down traces, log units). Calibration bars: horizontal bar ¼ 100 ms, vertical bar ¼ 100 lV, top and bottom deflection
indicates positive and negative voltage, respectively. (B, C) We reported the transfer curve for a-wave (B) and b-wave (C) amplitude (lV)
recorded at different light intensities (log cd s/m2) for stimulation of right (R) and left (L) eye (n¼5). (D) Representative traces recorded at
three different luminances (top-down traces, log units) in LE rats, LE rats whose eye was intraocularly injected with vehicle (LEþVeh; NaCl
0.9%, 2 lL), and LE rats whose eye was intraocularly injected with BDNF (LE þ BDNF; 2 lL of hBDNF at the concentration of 1 lg/lL).
Calibration bars: horizontal bar ¼ 100 ms, vertical bar ¼ 100 lV, top and bottom deflection indicates positive and negative voltage,
respectively. LE dramatically decreased the a- and b-wave amplitude at different luminances; BDNF injection partially prevented the fERG
impairment. (E) The transfer curve for a-wave amplitude (lV) recorded at different light intensities (log cd s/m2). (F) The transfer curve for
b-wave amplitude (lV) recorded at different light intensities (log cd s/m2). The results in E and F show that a- and b-wave amplitudes in
the LE eyes injected with BDNF (LEþ BDNF) were significantly higher compared to those measured in LE vehicle-treated eyes (LEþVeh);
five eyes for each group were analyzed (one-way ANOVA, *P , 0.05).
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ular injection of BDNF before LE was able to
prevent, at least partially, the fERG impairment
(Figs. 1D, 1E, 1F); as clearly visible in Figure 1, the
fERG was nearly abolished by LE with a- and b-wave
amplitude dramatically decreased at all light intensi-
ties (Figs. 1D, 1E, 1F, LEþ vehicle and LE). Previous
data by our group showed that the retinal BDNF
level was significantly increased compared to untreat-
ed eye, when BDNF was intraocularly injected at the
same concentration of 1 lg/lL and measured 6 hours
after by ELISA.15 Thus, intraocular injection of
BDNF was able to prevent impairment of fERG
caused by LE.
The next step was to know whether BDNF topical
application to the eye was capable of increasing the
retinal content of BDNF. We used BDNF at the
concentration of 12 lg/lL in 0.9% NaCl according to
recent results obtained in the mouse eye.15 In Figure
2, we compared BDNF retinal level in the rat using
intravitreal injection and topical eye treatment.
Retinal BDNF level was significantly increased
respect to the contralateral eye when BDNF was
intravitreally injected (Fig. 2A) and topically applied
(Fig. 2B). In addition, we explored whether different
BDNF ophthalmic-based preparations characterized
by high viscosity should facilitate the administration
and continuous delivery of BDNF to the eye as liquid
drop. To increase the viscosity of the solution, we
used sodium CMC or the polysaccharide fraction of
TSP (ophthalmic preparation frequently used as
artificial tear). TSP was previously utilized as vehicle
to carry pharmacologically active molecules for
topical treatment of the eye surface.19–22; TSP is able
to facilitate the absorption of active molecules by
increasing their retention time on ocular surface.
BDNF (5 lL at the concentration of 24 lg/lL in
physiological solution) was added to 0.4% CMC and
0.5 % TSP (5 lL) to have a final concentration of 12
lg/lL in one drop (10 lL) of 0.2% CMC and 0.25 %
TSP, respectively. Results in Figure 3 (A) showed that
single drop application of BDNF/TSP (6 hours after
treatment, n¼ 5, mean¼ 478.6 pg/mg protein, SEM¼
85.5) induced a significant increase of BDNF level in
the retina compared to control vehicle treated eyes (6
hours after treatment, n ¼ 5, mean ¼ 46.6 pg/mg
protein, SEM ¼ 16.8), BDNF/NaCl (n ¼ 5, mean ¼
239.98, SEM¼ 80.44), and BDNF/CMC (n¼ 5, mean
¼ 26.91, SEM ¼ 3.6) topical eye treatment. Interest-
ingly, similar results were obtained when BDNF was
measured in homogenates from the optic nerve of the
treated eye (Fig. 3B). The pharmacokinetic study of
BDNF/TSP topical eye application showed that
BDNF level in the retina (Fig. 4A) and optic nerve
(Fig. 4B) was significantly higher when measured 6
hours after treatment returning slowly toward basal
level by 24 hours; importantly, 12 hours after
treatment, the level of the protein in the retina was
still elevated over basal value (n ¼ 4, *P , 0.05).The
reported results suggest that TSP represents a suitable
vehicle for topical eye BDNF treatment.
Having demonstrated that a single drop of BDNF/
TSP to the eye is able to increase the rat retinal
content of BDNF, similarly to our recent results in
mouse retina,15 we afforded the question of whether
this BDNF delivery was sufficient to prevent the
Figure 2. Retinal level of BDNF following intravitreal and topical
eye treatment. (A) The histogram shows the rat retinal BDNF level
(pg/mg protein, ELISA) in the BDNF injected eye (BDNF
concentration ¼ 1 lg/lL in physiological solution, volume 2 lL;
n ¼ 5 retinas) and vehicle injected eye (physiological solution,
volume ¼ 2 lL; n ¼ 5 retinas). (B) The histogram reports the rat
retinal level of BDNF following single topical eye treatment with
BDNF (concentration ¼ 12 lg/lL, volume ¼ 10 lL, n ¼ 5 retinas)
respect to vehicle treated eye (physiological solution, volume¼ 10
lL). Retinal level of BDNF was determined by ELISA 6 hours after
treatment; *P , 0.05 (Student’s t-test).
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impairment of retinal responses to flash and photo-
receptor degeneration that follows a prolonged
exposition to constant bright light in albino rats
(light-damage). Seven days after LE (calculated from
the first day of LE), rats were anesthetized and dark
adapted for fERG recordings; as clearly visible in
Figure 5 (A), the fERG was nearly abolished by LE
with a- and b-wave amplitude dramatically decreased
at different light intensities. We used one single drop
containing BDNF/TSP (10 lL, 12 lg/lL of BDNF in
0.25% TSP) in the conjunctival fornix 3 hours before
LE. At first, we controlled that BDNF/TSP treatment
did not affect fERG in normal rats (n¼ 3). We found
that one drop of BDNF/TSP did not impact on
retinal responses to light as evaluated by recording the
dark adapted fERG 12 and 24 hours after the
treatment (data not shown). Remarkably, topical
eye application of BDNF/TSP before LE was able to
preserve fERG responses and to prevent dramatic a-
and b-wave alteration in rats exposed to LE and
recorded 7 days after (Fig. 5A, LE þ BDNF). In
Figure 5 (B, C), we reported the transfer curve for a-
and b-wave amplitude at different light intensities
showing that a- and b-wave amplitudes in the eyes
treated with BDNF/TSP before LE were significantly
higher compared to those measured in vehicle-treated
eyes (LEþvehicle) and untreated eyes (LE), at least in
the range of luminances comprised between 0.1 and
20 cd s/m2. Thus, increasing the retinal content of
BDNF by topical eye application was capable of
preventing the disappearance of retinal responses to
flash in the light-damage model.
Also, we investigated whether topical eye applica-
tion of BDNF might prevent alteration of photore-
ceptors after LE. We conducted an histological
analysis of retinas (Figs. 6A, 6B, 6C) using the
fluorescent dye Propidium Iodide and confocal
microscopy; at the end of the recording sessions, the
retinas were processed and analyzed. We investigated
the retinas from eyes treated with one single drop of
BDNF/TSP (10 lL, 12 lg/lL of BDNF in 0.25%
TSP; LE þ BDNF), eyes treated with vehicle (TSP
0.25%; LE þ vehicle), untreated eyes (LE), and
unexposed eyes (CycL). In Figure 6 (A, B) it is visible
that LE for 48 hours dramatically reduced the
Figure 3. Topical eye application of BDNF increases BDNF level in
the retina and optic nerve. We applied one single drop (10 lL) of
different solutions (NaCl 0.9%, TSP 0.25%, CMC 0.2%) containing
BDNF (12 lg/lL BDNF) at the level of conjunctival fornix in Wistar
rats; the contralateral eye was treated with different solutions used
for preparing BDNF. To increase the viscosity of solution, we used
sodium carboxymethyl cellulose (CMC, 0.2%) and the
polysaccharide fraction of TSP (0.25%). Our results show that
single drop application of BDNF/TSP (12 lg/lL BDNF in 0.25% TSP)
induced a significant increase of BDNF level in the retina (A) and
optic nerve (B), compared to control vehicle treated eyes, BDNF/
NaCl and BDNF/CMC topical eye treatment (n ¼ 5 retinas in each
group, *P, 0.05). Retinal level of BDNF was determined by ELISA 6
hours after treatment; *P , 0.05 (Student’s t-test).
Figure 4. The pharmacokinetic study of BDNF/TSP topical
application showed that BDNF level in the retina (A) and optic
nerve (B) was significantly higher when measured 6 hours after
treatment returning slowly towards basal level by 24 hours;
importantly, 12 hours after treatment the level of the protein in the
retina was still elevated over basal value (n¼ 5, *P , 0.05).
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photoreceptor rows and photoreceptor ONL thick-
ness in both the central and peripheral retina; in the
ONL, the normal 10 to 12 rows of photoreceptor
nuclei present in the rat retina of eyes unexposed to
light (rats reared on a 12-hour light/dark cycle, CycL)
reduced to 3 to 4 rows both in the central and
peripheral retina of eyes exposed to bright light in
agreement to previous results12,13; accordingly, the
thickness of ONL in LE rats was strongly reduced.
The histograms in C showed a significantly higher
number of rows of photoreceptor nuclei in the LE
eyes treated with single drop of BDNF/TSP com-
pared to vehicle-treated retina; this photoreceptor
rescue was present both in the central and peripheral
retina as also assessed by measuring the thickness of
ONL (Fig. 6C).
Thus, topical eye treatment with BDNF in the
form of collyrium represents a suitable, reliable, and
noninvasive tool to increase the retinal content of
BDNF up to a level capable of exerting neuroprotec-
tion toward photoreceptors injured by light.
Discussion
The main result obtained in the present paper
indicates that BDNF following topical eye applica-
tion can reach the retina inducing the increase of
BDNF protein level both in the retina and optic nerve
of albino rats in agreement to what was recently
reported in the mouse.15 Remarkably, topical eye
treatment with BDNF mitigates the retinal damage
that follows an exposure to continuous bright light in
albino rats.
Light-damage is an in vivo model used to induce
synchronized and fast photoreceptor cell death by
apoptosis. Photoreceptor death by apoptosis is the
final step of several retinal dystrophies including
inherited diseases such as the family of Retinitis
pigmentosa and age-related senile macular degenera-
tion. Previous studies investigated the efficacy of
neurotrophic factors to prevent photoreceptor degen-
eration; b- and a-FGF, GDNF, CNTF, and BDNF
resulted suitable agents to prevent cell death in light
damage.2 In particular, b-FGF and GDNF are
thought to exert a direct trophic action on photore-
ceptors that express b-FGF and GDNF receptors.23
BDNF was also consistently reported to promote
photoreceptor survival in light damage,12,13 including
cones,24 although its specific receptors are largely
absent in these retinal cells; indeed, low expression of
TrkB has been described only in one cone subtype.25
This supports the possibility that BDNF might induce
Figure 5. Topical eye application of BDNF prevents fERG
impairment. (A) One week after LE, fERG was evoked by different
luminances (top-down traces, log units) and recorded from the
untreated eye (left column, LE), eye treated with vehicle (middle
column, LEþ vehicle, TSP 0.25%, 1 drop¼ 10 lL), eye treated with
BDNF/TSP (right column, LEþ BDNF; 12 lg/lL BDNF in 0.25% TSP,
1 drop ¼ 10 lL). Topical application of BDNF/TSP before LE was
able to partially preserve fERG responses recorded 1 week after
light damage. Calibration: horizontal bar¼100 ms, vertical bar¼50
lV. (B, C) In panels B and C, we reported the transfer curve for a-
wave and b-wave amplitude (lV), respectively, recorded at
different light intensities (log cd s/m2). The results show that a-
and b-wave amplitudes in the LE eyes treated with BDNF/TSP (LEþ
BDNF) were significantly higher compared to those measured in LE
vehicle-treated eyes (LE þ Veh); four eyes for each group were
analyzed (one-way ANOVA, *P , 0.05).
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signaling in other cells of the retina, thus acting
indirectly on photoreceptors.26 Indeed, Mu¨ller cells
express TrkB and react to BDNF exposure by
increasing the release of b-FGF and GDNF.23 In
agreement to this hypothesis, recent results on TrkB
knockout mice showed that BDNF signaling in
retinal glia has important roles in protection of
retinal cells.27
Regardless of whether BDNF acts directly or
indirectly on photoreceptors, this neurotrophin was
widely applied to prevent photoreceptor apoptosis
that follows an exposition to continuous bright light.2
So far, BDNF as well as other neurotrophic factors,
have been administered to the internal ocular tissues
mainly by intravitreal or retrobulbar injection, two
methods of treatment that involve the risk of various
complications such as the ocular bulb perforation,
infections, and lesions.14 These unwanted effects
prevented an extensive use of neurotrophic factors
as survival promoting agents in retinal diseases.
Figure 6. Using Propidium Iodide staining and confocal microscopy, we conducted an histological analysis of ONL from the central and
peripheral retina of normal eyes (rats reared on a 12-hour light/dark cycle; Cycl), LE eyes treated with vehicle (LEþvehicle; TSP 0.25%) and
LE eyes treated with one single drop of BDNF/TSP (LEþBDNF; 12 lg/lL in 0.25% TSP). (A) Top panel and bottom panel refer to the central
and peripheral retina, respectively, of a rat reared on a12-hour light/dark cycle (Cycl). (B) One week after LE, the rows of photoreceptor
nuclei appear strongly reduced (left column, LE þ vehicle) both in the central (top row) and peripheral retina (bottom row). BDNF/TSP
topical eye treatment was able to prevent the dramatic lost of photoreceptors in light-damage (right column, LE þ BDNF). Horizontal
calibration bar ¼ 20 lm. Panel C reports histograms showing a significantly higher (*P , 0.05) number of photoreceptor rows (left
histogram) and greater ONL thickness (right histogram) in the light-damaged central and peripheral retina of rats whose eye was treated
with BDNF (LEþBDNF) respect to contralateral vehicle-treated eye (LEþvehicle), untreated eye (LE); CycL refers to retina of rats reared on
a 12-hour light/dark cycle. Four retinas for each group were processed and analyzed.
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Recently, we reported that repeated topical eye
applications of BDNF were able to rescue retinal
responses in a murine model of glaucoma.15 Here, to
facilitate a prolonged delivery of BDNF applied in
the conjunctival fornix we used a TSP, a polysaccha-
ride fraction of TSP, largely employed as artificial
tear and vehicle to carry pharmacological active
molecules.19–22 We reported that the efficacy of TSP
to facilitate the increase of BDNF retinal level is
higher than that of physiological solution and CMC.
Pharmacokinetic study of BDNF/TSP topical eye
application showed that retinal BDNF level was
higher than in control eye 6 hours after application
remaining elevated for 12 hours and returning to
basal value in 24 hours.
In the second part of the present paper, we
afforded the fundamental question of whether topical
eye treatment with BDNF was able to ameliorate the
retinal alterations induced by prolonged exposition to
continuous bright light in albino rats. We showed that
BDNF topical application to the eye immediately
before LE was able to conserve the retinal response to
light and to promote survival of photoreceptors in LE
albino rats, similarly to intraocular injection. A single
intraocular injection of BDNF is probably more
effective than a single topical eye BDNF application
in preserving fERG amplitudes at different luminanc-
es, possibly for different dynamics in the release to
vitreous humor, retina, and optic nerve.
Pharmacological compounds can reach the retina
through two routes when topically applied to the eye:
through the cornea and through the conjunctiva.
Since BDNF, as well as other neurotrophic factors, is
high molecular protein, it is very difficult that it can
reach the retina by crossing the cornea. In a previous
report, NGF was topically applied at the level of
conjunctival fornix similarly to the method followed
in the present paper. By measuring the NGF level in
the conjunctiva and/or sclera, the authors suggested
that NGF reached the posterior eye segment travel-
ling through conjunctiva/sclera.28 Trans-scleral deliv-
ery requires BDNF to permeate through several
layers of ocular tissue (sclera, Bruch’s membrane-
choroid, retinal pigment epithelium) to reach the
retina. We expect that novel trans-scleral drug
delivery systems might ameliorate delivery of drugs
to retina; for instance, we reported that TSP is more
effective than physiological solution and CMC.
The alternative possibility is that BDNF might be
delivered to the internal ocular tissues after absorp-
tion in choroidal tissue and plasma transport. In our
experimental conditions, the contralateral eyes treated
with vehicle did not show increased BDNF retinal
levels respect to basal values and, more importantly,
the retinas of vehicle treated eye resulted unprotected
from light damage, thus contrary to what was
expected in the case that BDNF was adequately
adsorbed and transported to several tissues including
the contralateral untreated eye.
The present results suggest that topical application
to the eye of BDNF and, possibly, additional survival
promoting agents, might represent a new therapeutic
strategy to protect retinal cells from dysfunction/
degeneration. In particular, we reported that the
topical eye treatment with BDNF prevents impair-
ment of flash ERG and loss of photoreceptors in light
damage. It remains to be proved whether protracted
topical eye treatments with BDNF will be feasible for
the human retina that needs to be maintained in a
functional state for a longer time to prevent cell
degeneration in different retinal diseases.
Acknowledgments
We thank Silvia Bisti, Enrica Strettoi, and
Vincenzo Parisi for critical reading of the manuscript
and helpful suggestions. We thank Carlo Orsini and
Renzo di Renzo for hardware and software technical
assistance, and S. Wilson for revising the English style
of the manuscript.
The present work was supported by the Italian
Ministry of Research (Grant PRIN, 2010) to LD. LD,
MS, and LG are the authors of an European patent
(EP 250362 B1) entitled: Ophthalmic preparations
based on BDNF (brain-derived neurotrophic factor)
and their use.
Disclosure: E. Cerri, None; N. Origlia, None; B.
Falsini, None; D. Barloscio, None; C. Fabiani, None;
M. Sanso`, None; S. Ottino, None; L. Giovannini,
None; L. Domenici, None
References
1. Arancio O, Chao MV. Neurotrophins, synaptic
plasticity and dementia. Curr Opin Neurobiol.
2007;17:325–330.
2. Wenzel A, Grimm C, Samardzija M, Reme´ CE.
Molecular mechanisms of light-induced photore-
ceptor apoptosis and neuroprotection for retinal
9 TVST j 2015 j Vol. 4 j No. 6 j Article 1
Cerri et al.
Downloaded From: http://tvst.arvojournals.org/pdfaccess.ashx?url=/data/Journals/TVST/934654/ on 11/02/2015
degeneration. Prog Retin Eye Res. 2005;24:275–
306.
3. Mansour-Robaey S, Clarke DB, Wang YC, Bray
GM, Aguayo AJ. Effects of ocular injury and
administration of brain-derived neurotrophic
factor on survival and regrowth of axotomized
retinal ganglion cells. Proc Natl Acad Sci U S A.
1994;91;1632–1636.
4. Peinado-Ramo´n P, Salvador M, Villegas-Pe´rez
MP, Vidal-Sanz M. Effects of axotomy and
intraocular administration of NT-4, NT-3, and
brain-derived neurotrophic factor on the survival
of adult rat retinal ganglion cells. A quantitative
in vivo study. Invest Ophthalmol Vis Sci. 1996;37;
489–500.
5. Kaplan DR, Miller FD. Signal transduction by
the neurotrophin receptors. Curr Opin Cell Biol.
1997;9;213–221.
6. von Bartheld CS. Neurotrophins in the develop-
ing and regenerating visual system. Histol Histo-
pathol. 1998;13;437–459.
7. Bennett JL, Zeiler SR, Jones KR. Patterned
expression of BDNF and NT-3 in the retina and
anterior segment of the developing mammalian
eye. Invest Ophthalmol Vis Sci. 1999;40:2996–
3005.
8. Wahlin KJ, Campochiaro PA, Zack DJ, Adler R.
Neurotrophic factors cause activation of intracel-
lular signaling pathways in Mu¨ller cells and other
cells of the inner retina, but not photoreceptors.
Invest Ophthalmol Vis Sci. 2000;41:927–936.
9. Wahlin KJ, Adler R, Zack DJ, Campochiaro PA.
Neurotrophic signaling in normal and degenerat-
ing rodent retinas. Exp Eye Res. 2001;73:693–701.
10. Rohrer B, Korenbrot JI, LaVail MM, Reichardt
LF, Xu B. Role of neurotrophin receptor TrkB in
the maturation of rod photoreceptors and estab-
lishment of synaptic transmission to the inner
retina. J Neurosci. 1999;19;8919–8930.
11. Cellerino A, Pinzo´n-Duarte G, Carroll P, Kohler
K. Brain-derived neurotrophic factor modulates
the development of the dopaminergic network in
the rodent retina. J Neurosci. 1998;18:3351–3362.
12. LaVail MM, Unoki K, Yasumura D, Matthes
MT, Yancopoulos GD, Steinberg RH. Multiple
growth factors, cytokines, and neurotrophins
rescue photoreceptors from the damaging effects
of constant light. Proc Natl Acad Sci U S A. 1992;
89;11249–11253.
13. LaVail MM, Yasumura D, Matthes MT, et al.
Protection of mouse photoreceptors by survival
factors in retinal degenerations. Invest Ophthal-
mol Vis Sci. 1998;39:592–602.
14. Kezic JM, Chrysostomou V, Trounce IA, McMe-
namin PG, Crowston JG. Effect of anterior
chamber cannulation and acute IOP elevation
on retinal macrophages in the adult mouse. Invest
Ophthalmol Vis Sci. 2013;54:3028–3036.
15. Domenici L, Origlia N, Falsini B, et al. Rescue of
retinal function by BDNF in a mouse model of
glaucoma. PLoS One. 2014;9;e115579.
16. Surace EM, Domenici L, Cortese K, et al.
Amelioration of both functional and morpholog-
ical abnormalities in the retina of a mouse model
of ocular albinism following AAV-mediated gene
transfer. Mol Ther. 2005;12;652–658.
17. Allocca M, Di Vicino U, Petrillo M, Carlomagno
F, Domenici L, Auricchio A Constitutive and
AP20187-induced Ret activation in photorecep-
tors does not protect from light-induced damage.
Invest Ophthalmol Vis Sci. 2007;48:5199–5206.
18. Maccarone R, Di Marco S, Bisti S. Saffron
supplement maintains morphology and function
after exposure to damaging light in mammalian
retina. Invest Ophthalmol Vis Sci. 2008;49;1254–
1261.
19. Burgalassi S, Raimondi L, Pirisino R, Banchelli
G, Boldrini E, Saettone MF. Effect of xyloglucan
(tamarind seed polysaccharide) on conjunctival
cell adhesion to laminin and on corneal epitheli-
um wound healing. Eur J Ophthalmol. 2000;10:
71–76.
20. Ghelardi E, Tavanti A, Davini P, et al. A
mucoadhesive polymer extracted from tamarind
seed improves the intraocular penetration and
efficacy of rufloxacin in topical treatment of
experimental bacterial keratitis. Antimicrob
Agents Chemother. 2004;48:3396–3401.
21. Rolando M, Valente C. Establishing the tolera-
bility and performance of tamarind seed polysac-
charide (TSP) in treating dry eye syndrome:
results of a clinical study. BMC Ophthalmol.
2007;7:5.
22. Uccello-Barretta G, Nazzi S, Balzano F, et al.
Enhanced affinity of ketotifen toward tamarind
seed polysaccharide in comparison with hydrox-
yethylcellulose and hyaluronic acid: a nuclear
magnetic resonance investigation. Bioorg Med
Chem. 2008;16:7371–7376.
23. Harada T, Harada C, Kohsaka S, et al. Microg-
lia-Mu¨ller glia cell interactions control neuro-
trophic factor production during light-induced
retinal degeneration. J Neurosci. 2002;22:9228–
9236.
24. Ortı´n-Martı´nez A, Valiente-Soriano FJ, Garcı´a-
Ayuso D, et al. A novel in vivo model of focal
light emitting diode-induced cone-photoreceptor
10 TVST j 2015 j Vol. 4 j No. 6 j Article 1
Cerri et al.
Downloaded From: http://tvst.arvojournals.org/pdfaccess.ashx?url=/data/Journals/TVST/934654/ on 11/02/2015
phototoxicity: neuroprotection afforded by bri-
monidine, BDNF, PEDF or bFGF. PLoS One.
2014;9:e113798, PMID 25464513.
25. Di Polo A, Cheng L, Bray GM, Aguayo AJ.
Colocalization of TrkB and brain-derived neuro-
trophic factor proteins in green-red-sensitive cone
outer segments. Invest Ophthalmol Vis Sci. 2000;
41:4014–4021.
26. Gauthier R, Joly S, Pernet V, Lachapelle P, Di
Polo A. Brain-derived neurotrophic factor gene
delivery to mu¨ller glia preserves structure and
function of light-damaged photoreceptors. Invest
Ophthalmol Vis Sci. 2005;46:3383–3392.
27. Harada C, Guo X, Namekata K, et al. Glia- and
neuron-specific functions of TrkB signalling
during retinal degeneration and regeneration.
Nat Commun. 2011;2:189–198.
28. Lambiase A, Tirassa P, Micera A, Aloe L, Bonini
S. Pharmacokinetics of conjunctivally applied
nerve growth factor in the retina and optic nerve
of adult rats. Invest Ophthalmol Vis Sci. 2005;46:
3800–3806.
11 TVST j 2015 j Vol. 4 j No. 6 j Article 1
Cerri et al.
Downloaded From: http://tvst.arvojournals.org/pdfaccess.ashx?url=/data/Journals/TVST/934654/ on 11/02/2015
